{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T11:47:38Z","timestamp":1794484058054,"version":"4.9.1"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T00:00:00Z","timestamp":1708473600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T00:00:00Z","timestamp":1708473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Anesth Analg Crit Care"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Patients with septic shock who experience refractory hypotension despite adequate fluid resuscitation and high-dose noradrenaline have high mortality rates. To improve outcomes, evidence-based guidelines recommend starting a second vasopressor, such as vasopressin, if noradrenaline doses exceed 0.5 \u00b5g\/kg\/min. Recently, promising results have been observed in treating refractory hypotension with angiotensin II, which has been shown to increase mean arterial pressure and has been associated with improved outcomes. This narrative review aims to provide an overview of the pathophysiology of the renin-angiotensin system and the role of endogenous angiotensin II in vasodilatory shock with a focus on how angiotensin II treatment impacts clinical outcomes and on identifying the population that may benefit most from its use.<\/jats:p>","DOI":"10.1186\/s44158-024-00150-w","type":"journal-article","created":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T12:02:30Z","timestamp":1708516950000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Angiotensin II therapy in refractory septic shock: which patient can benefit most? A narrative review"],"prefix":"10.1186","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9022-1768","authenticated-orcid":false,"given":"Irene","family":"Coloretti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Genovese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Pedro","family":"Teixeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anusha","family":"Cherian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricard","family":"Ferrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Landoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Leone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Girardis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan D.","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,21]]},"reference":[{"key":"150_CR1","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2016.0287","volume":"315","author":"M Singer","year":"2016","unstructured":"Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M et al (2016) The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 315:801\u2013810. https:\/\/doi.org\/10.1001\/jama.2016.0287","journal-title":"JAMA"},{"key":"150_CR2","doi-asserted-by":"publisher","first-page":"154258","DOI":"10.1016\/j.jcrc.2023.154258","volume":"75","author":"E Antonucci","year":"2023","unstructured":"Antonucci E, Polo T, Giovini M, Girardis M, Martin-Loeches I, Nielsen ND et al (2023) Refractory septic shock and alternative wordings: a systematic review of literature. J Crit Care 75:154258. https:\/\/doi.org\/10.1016\/j.jcrc.2023.154258","journal-title":"J Crit Care"},{"key":"150_CR3","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1007\/s00134-018-5218-5","volume":"44","author":"K Maheshwari","year":"2018","unstructured":"Maheshwari K, Nathanson BH, Munson SH, Khangulov V, Stevens M, Badani H et al (2018) The relationship between ICU hypotension and in-hospital mortality and morbidity in septic patients. Intensive Care Med 44:857\u2013867. https:\/\/doi.org\/10.1007\/s00134-018-5218-5","journal-title":"Intensive Care Med"},{"key":"150_CR4","doi-asserted-by":"publisher","first-page":"e1063","DOI":"10.1097\/CCM.0000000000005337","volume":"49","author":"L Evans","year":"2021","unstructured":"Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C et al (2021) Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Crit Care Med 49:e1063\u2013e1143. https:\/\/doi.org\/10.1097\/CCM.0000000000005337","journal-title":"Crit Care Med"},{"key":"150_CR5","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1007\/s00134-008-1219-0","volume":"34","author":"JA Myburgh","year":"2008","unstructured":"Myburgh JA, Higgins A, Jovanovska A, Lipman J, Ramakrishnan N, Santamaria J et al (2008) A comparison of epinephrine and norepinephrine in critically ill patients. Intensive Care Med 34:2226\u20132234. https:\/\/doi.org\/10.1007\/s00134-008-1219-0","journal-title":"Intensive Care Med"},{"key":"150_CR6","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1124\/jpet.120.000146","volume":"375","author":"N Barabutis","year":"2020","unstructured":"Barabutis N, Marinova M, Solopov P, Uddin MA, Croston GE, Reinheimer TM et al (2020) Protective Mechanism of the Selective Vasopressin V1A Receptor Agonist Selepressin against Endothelial Barrier Dysfunction. J Pharmacol Exp Ther 375:286\u2013295. https:\/\/doi.org\/10.1124\/jpet.120.000146","journal-title":"J Pharmacol Exp Ther"},{"key":"150_CR7","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s13054-016-1306-5","volume":"20","author":"LS Chawla","year":"2016","unstructured":"Chawla LS, Busse LW, Brasha-Mitchell E, Alotaibi Z (2016) The use of angiotensin II in distributive shock. Crit Care 20:137. https:\/\/doi.org\/10.1186\/s13054-016-1306-5","journal-title":"Crit Care"},{"key":"150_CR8","doi-asserted-by":"publisher","first-page":"e550","DOI":"10.1097\/CCM.0000000000000397","volume":"42","author":"TD Corr\u00eaa","year":"2014","unstructured":"Corr\u00eaa TD, Jeger V, Pereira AJ, Takala J, Djafarzadeh S, Jakob SM (2014) Angiotensin II in septic shock: effects on tissue perfusion, organ function, and mitochondrial respiration in a porcine model of fecal peritonitis. Crit Care Med 42:e550-559. https:\/\/doi.org\/10.1097\/CCM.0000000000000397","journal-title":"Crit Care Med"},{"key":"150_CR9","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1056\/NEJMoa1704154","volume":"377","author":"A Khanna","year":"2017","unstructured":"Khanna A, English SW, Wang XS, Ham K, Tumlin J, Szerlip H et al (2017) Angiotensin II for the Treatment of Vasodilatory Shock. N Engl J Med 377:419\u2013430. https:\/\/doi.org\/10.1056\/NEJMoa1704154","journal-title":"N Engl J Med"},{"key":"150_CR10","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1159\/000078716","volume":"143","author":"A Ichihara","year":"2004","unstructured":"Ichihara A, Kobori H, Nishiyama A, Navar LG (2004) Renal renin-angiotensin system. Contrib Nephrol 143:117\u2013130. https:\/\/doi.org\/10.1159\/000078716","journal-title":"Contrib Nephrol"},{"key":"150_CR11","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1111\/j.1365-2796.2008.01981.x","volume":"264","author":"F Fyhrquist","year":"2008","unstructured":"Fyhrquist F, Saijonmaa O (2008) Renin-angiotensin system revisited. J Intern Med 264:224\u2013236. https:\/\/doi.org\/10.1111\/j.1365-2796.2008.01981.x","journal-title":"J Intern Med"},{"key":"150_CR12","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.tem.2007.05.001","volume":"18","author":"R Kumar","year":"2007","unstructured":"Kumar R, Singh VP, Baker KM (2007) The intracellular renin-angiotensin system: a new paradigm. Trends Endocrinol Metab 18:208\u2013214. https:\/\/doi.org\/10.1016\/j.tem.2007.05.001","journal-title":"Trends Endocrinol Metab"},{"key":"150_CR13","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1152\/physrev.00036.2005","volume":"86","author":"M Paul","year":"2006","unstructured":"Paul M, Poyan Mehr A, Kreutz R (2006) Physiology of local renin-angiotensin systems. Physiol Rev 86:747\u2013803. https:\/\/doi.org\/10.1152\/physrev.00036.2005","journal-title":"Physiol Rev"},{"key":"150_CR14","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1097\/CCM.0000000000005143","volume":"50","author":"M Jeyaraju","year":"2022","unstructured":"Jeyaraju M, McCurdy MT, Levine AR, Devarajan P, Mazzeffi MA, Mullins KE et al (2022) Renin kinetics are superior to lactate kinetics for predicting in-hospital mortality in hypotensive critically Ill patients. Crit Care Med 50:50\u201360. https:\/\/doi.org\/10.1097\/CCM.0000000000005143","journal-title":"Crit Care Med"},{"key":"150_CR15","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1097\/CCM.0000000000003544","volume":"47","author":"PJ Gleeson","year":"2019","unstructured":"Gleeson PJ, Crippa IA, Mongkolpun W, Cavicchi FZ, Van Meerhaeghe T, Brimioulle S et al (2019) Renin as a marker of tissue-perfusion and prognosis in critically Ill patients. Crit Care Med 47:152\u2013158. https:\/\/doi.org\/10.1097\/CCM.0000000000003544","journal-title":"Crit Care Med"},{"key":"150_CR16","doi-asserted-by":"publisher","first-page":"2522","DOI":"10.1161\/01.CIR.0000074786.92067.AA","volume":"107","author":"JO Kokkonen","year":"2003","unstructured":"Kokkonen JO, Lindstedt KA, Kovanen PT (2003) Role for chymase in heart failure: angiotensin II-dependent or -independent mechanisms? Circulation 107:2522\u20132524. https:\/\/doi.org\/10.1161\/01.CIR.0000074786.92067.AA","journal-title":"Circulation"},{"key":"150_CR17","doi-asserted-by":"publisher","first-page":"C82","DOI":"10.1152\/ajpcell.00287.2006","volume":"292","author":"PK Mehta","year":"2007","unstructured":"Mehta PK, Griendling KK (2007) Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol 292:C82-97. https:\/\/doi.org\/10.1152\/ajpcell.00287.2006","journal-title":"Am J Physiol Cell Physiol"},{"key":"150_CR18","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/01.mnh.0000196146.65330.ea","volume":"15","author":"I Fleming","year":"2006","unstructured":"Fleming I, Kohlstedt K, Busse R (2006) The tissue renin-angiotensin system and intracellular signalling. Curr Opin Nephrol Hypertens 15:8\u201313. https:\/\/doi.org\/10.1097\/01.mnh.0000196146.65330.ea","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"150_CR19","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1097\/00041552-200501000-00011","volume":"14","author":"RM Carey","year":"2005","unstructured":"Carey RM (2005) Update on the role of the AT2 receptor. Curr Opin Nephrol Hypertens 14:67\u201371. https:\/\/doi.org\/10.1097\/00041552-200501000-00011","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"150_CR20","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1146\/annurev.ph.54.030192.001303","volume":"54","author":"KM Baker","year":"1992","unstructured":"Baker KM, Booz GW, Dostal DE (1992) Cardiac actions of angiotensin II: Role of an intracardiac renin-angiotensin system. Annu Rev Physiol 54:227\u2013241. https:\/\/doi.org\/10.1146\/annurev.ph.54.030192.001303","journal-title":"Annu Rev Physiol"},{"key":"150_CR21","doi-asserted-by":"publisher","unstructured":"Ruiz-Ortega M, Ruperez M, Lorenzo O, Esteban V, Blanco J, Mezzano S, et al. (2002)\u00a0 Angiotensin II regulates the synthesis of proinflammatory cytokines and chemokines in the kidney. Kidney Int Suppl S12\u201322\u00a0https:\/\/doi.org\/10.1046\/j.1523-1755.62.s82.4.x","DOI":"10.1046\/j.1523-1755.62.s82.4.x"},{"key":"150_CR22","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s00125-005-0101-7","volume":"49","author":"RD Ramracheya","year":"2006","unstructured":"Ramracheya RD, Muller DS, Wu Y, Whitehouse BJ, Huang GC, Amiel SA et al (2006) Direct regulation of insulin secretion by angiotensin II in human islets of Langerhans. Diabetologia 49:321\u2013331. https:\/\/doi.org\/10.1007\/s00125-005-0101-7","journal-title":"Diabetologia"},{"key":"150_CR23","doi-asserted-by":"publisher","first-page":"367","DOI":"10.2337\/diabetes.55.02.06.db05-1022","volume":"55","author":"KY Chu","year":"2006","unstructured":"Chu KY, Lau T, Carlsson P-O, Leung PS (2006) Angiotensin II type 1 receptor blockade improves beta-cell function and glucose tolerance in a mouse model of type 2 diabetes. Diabetes 55:367\u2013374. https:\/\/doi.org\/10.2337\/diabetes.55.02.06.db05-1022","journal-title":"Diabetes"},{"key":"150_CR24","doi-asserted-by":"publisher","first-page":"3759","DOI":"10.1016\/S0021-9258(18)34846-4","volume":"257","author":"FD Assimacopoulos-Jeannet","year":"1982","unstructured":"Assimacopoulos-Jeannet FD, Blackmore PF, Exton JH (1982) Studies of the interaction between glucagon and alpha-adrenergic agonists in the control of hepatic glucose output. J Biol Chem 257:3759\u20133765","journal-title":"J Biol Chem"},{"key":"150_CR25","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1001\/jama.1961.03040490020005","volume":"178","author":"F Del Greco","year":"1961","unstructured":"Del Greco F, Johnson DC (1961) Clinical experience with angiotensin II in the treatment of shock. JAMA 178:994\u2013999. https:\/\/doi.org\/10.1001\/jama.1961.03040490020005","journal-title":"JAMA"},{"key":"150_CR26","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1161\/01.cir.25.1.263","volume":"25","author":"JR Derrick","year":"1962","unstructured":"Derrick JR, Anderson JR, Roland BJ (1962) Adjunctive use of a biologic pressor agent, angiotensin, in management of shock. Circulation 25:263\u2013267. https:\/\/doi.org\/10.1161\/01.cir.25.1.263","journal-title":"Circulation"},{"key":"150_CR27","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/0002-9149(63)90036-5","volume":"11","author":"R Wedeen","year":"1963","unstructured":"Wedeen R, Zucker G (1963) Angiotensin II in the treatment of shock. Am J Cardiol 11:82\u201386. https:\/\/doi.org\/10.1016\/0002-9149(63)90036-5","journal-title":"Am J Cardiol"},{"key":"150_CR28","first-page":"639","volume":"14","author":"S Singh","year":"1966","unstructured":"Singh S, Malhotra RP (1966) Comparative study of angiotensin and nor-adrenaline in hypotensive states (shock). J Assoc Physicians India 14:639\u2013645","journal-title":"J Assoc Physicians India"},{"key":"150_CR29","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1097\/00003246-199108000-00020","volume":"19","author":"VL Thomas","year":"1991","unstructured":"Thomas VL, Nielsen MS (1991) Administration of angiotensin II in refractory septic shock. Crit Care Med 19:1084\u20131086. https:\/\/doi.org\/10.1097\/00003246-199108000-00020","journal-title":"Crit Care Med"},{"key":"150_CR30","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/0140-6736(93)90479-z","volume":"341","author":"T Jackson","year":"1993","unstructured":"Jackson T, Corke C, Agar J (1993) Enalapril overdose treated with angiotensin infusion. Lancet 341:703. https:\/\/doi.org\/10.1016\/0140-6736(93)90479-z","journal-title":"Lancet"},{"key":"150_CR31","unstructured":"Lisinopril overdose and management with intravenous angiotensin II - PubMed n.d. https:\/\/pubmed.ncbi.nlm.nih.gov\/7841571\/ (Accessed 24 Nov 2023)"},{"key":"150_CR32","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/j.1365-2125.1995.tb04546.x","volume":"40","author":"DE Newby","year":"1995","unstructured":"Newby DE, Lee MR, Gray AJ, Boon NA (1995) Enalapril overdose and the corrective effect of intravenous angiotensin II. Br J Clin Pharmacol 40:103\u2013104. https:\/\/doi.org\/10.1111\/j.1365-2125.1995.tb04546.x","journal-title":"Br J Clin Pharmacol"},{"key":"150_CR33","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1378\/chest.107.1.201","volume":"107","author":"J Ryding","year":"1995","unstructured":"Ryding J, Heslet L, Hartvig T, J\u00f8nsson V (1995) Reversal of \u201crefractory septic shock\u201d by infusion of amrinone and angiotensin II in an anthracycline-treated patient. Chest 107:201\u2013203. https:\/\/doi.org\/10.1378\/chest.107.1.201","journal-title":"Chest"},{"key":"150_CR34","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1016\/s0140-6736(95)91933-3","volume":"346","author":"GM Wray","year":"1995","unstructured":"Wray GM, Coakley JH (1995) Severe septic shock unresponsive to noradrenaline. Lancet 346:1604. https:\/\/doi.org\/10.1016\/s0140-6736(95)91933-3","journal-title":"Lancet"},{"key":"150_CR35","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1159\/000190280","volume":"77","author":"JL Tovar","year":"1997","unstructured":"Tovar JL, Bujons I, Ruiz JC, Iba\u00f1ez L, Salgado A (1997) Treatment of severe combined overdose of calcium antagonists and converting enzyme inhibitors with angiotensin II. Nephron 77:239. https:\/\/doi.org\/10.1159\/000190280","journal-title":"Nephron"},{"key":"150_CR36","first-page":"696","volume":"29","author":"A Desachy","year":"2000","unstructured":"Desachy A, Normand S, Fran\u00e7ois B, Cassat C, Gastinne H (2000) Vignon P [Refractory shock after converting enzyme inhibitor administration. Usefulness of angiotensin II]. Presse Med 29:696\u2013698","journal-title":"Presse Med"},{"key":"150_CR37","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1136\/adc.82.5.388","volume":"82","author":"M Yunge","year":"2000","unstructured":"Yunge M, Petros A (2000) Angiotensin for septic shock unresponsive to noradrenaline. Arch Dis Child 82:388\u2013389. https:\/\/doi.org\/10.1136\/adc.82.5.388","journal-title":"Arch Dis Child"},{"key":"150_CR38","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13613-022-01021-9","volume":"12","author":"MA Ammar","year":"2022","unstructured":"Ammar MA, Ammar AA, Wieruszewski PM, Bissell BD, T Long M, Albert L et al (2022) Timing of vasoactive agents and corticosteroid initiation in septic shock. Ann Intensive Care 12:47. https:\/\/doi.org\/10.1186\/s13613-022-01021-9","journal-title":"Ann Intensive Care"},{"key":"150_CR39","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s13054-019-2420-y","volume":"23","author":"LS Chawla","year":"2019","unstructured":"Chawla LS, Ostermann M, Forni L, Tidmarsh GF (2019) Broad spectrum vasopressors: a new approach to the initial management of septic shock? Crit Care 23:124. https:\/\/doi.org\/10.1186\/s13054-019-2420-y","journal-title":"Crit Care"},{"key":"150_CR40","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1097\/MCC.0000000000000517","volume":"24","author":"BJ Wakefield","year":"2018","unstructured":"Wakefield BJ, Sacha GL, Khanna AK (2018) Vasodilatory shock in the ICU and the role of angiotensin II. Curr Opin Crit Care 24:277\u2013285. https:\/\/doi.org\/10.1097\/MCC.0000000000000517","journal-title":"Curr Opin Crit Care"},{"key":"150_CR41","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s40560-020-00500-0","volume":"8","author":"L Zhong","year":"2020","unstructured":"Zhong L, Ji X-W, Wang H-L, Zhao G-M, Zhou Q, Xie B (2020) Non-catecholamine vasopressors in the treatment of adult patients with septic shock-evidence from meta-analysis and trial sequential analysis of randomized clinical trials. J Intensive Care 8:83. https:\/\/doi.org\/10.1186\/s40560-020-00500-0","journal-title":"J Intensive Care"},{"key":"150_CR42","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13054-022-03911-7","volume":"26","author":"PM Wieruszewski","year":"2022","unstructured":"Wieruszewski PM, Khanna AK (2022) Vasopressor Choice and Timing in Vasodilatory Shock. Crit Care 26:76. https:\/\/doi.org\/10.1186\/s13054-022-03911-7","journal-title":"Crit Care"},{"key":"150_CR43","doi-asserted-by":"publisher","first-page":"101193","DOI":"10.1016\/j.accpm.2023.101193","volume":"42","author":"M Leone","year":"2023","unstructured":"Leone M, Einav S, Antonucci E, Depret F, Lakbar I, Martin-Loeches I et al (2023) Multimodal strategy to counteract vasodilation in septic shock. Anaesth Crit Care Pain Med 42:101193. https:\/\/doi.org\/10.1016\/j.accpm.2023.101193","journal-title":"Anaesth Crit Care Pain Med"},{"key":"150_CR44","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13613-017-0261-x","volume":"7","author":"T Auchet","year":"2017","unstructured":"Auchet T, Regnier M-A, Girerd N, Levy B (2017) Outcome of patients with septic shock and high-dose vasopressor therapy. Ann Intensive Care 7:43. https:\/\/doi.org\/10.1186\/s13613-017-0261-x","journal-title":"Ann Intensive Care"},{"key":"150_CR45","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1378\/chest.12-1106","volume":"143","author":"SM Brown","year":"2013","unstructured":"Brown SM, Lanspa MJ, Jones JP, Kuttler KG, Li Y, Carlson R et al (2013) Survival after shock requiring high-dose vasopressor therapy. Chest 143:664\u2013671. https:\/\/doi.org\/10.1378\/chest.12-1106","journal-title":"Chest"},{"key":"150_CR46","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1097\/CCM.0000000000004476","volume":"48","author":"RJ Roberts","year":"2020","unstructured":"Roberts RJ, Miano TA, Hammond DA, Patel GP, Chen J-T, Phillips KM et al (2020) Evaluation of Vasopressor Exposure and Mortality in Patients With Septic Shock. Crit Care Med 48:1445\u20131453. https:\/\/doi.org\/10.1097\/CCM.0000000000004476","journal-title":"Crit Care Med"},{"key":"150_CR47","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.chest.2022.07.018","volume":"163","author":"R Sato","year":"2023","unstructured":"Sato R, Duggal A, Sacha GL, Rudoni MA, Yataco AC, Khanna AK et al (2023) The relationship between norepinephrine equivalent dose of vasopressors within 24 hours from the onset of septic shock and in-hospital mortality Rate. Chest 163:148\u2013151. https:\/\/doi.org\/10.1016\/j.chest.2022.07.018","journal-title":"Chest"},{"key":"150_CR48","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.jcrc.2013.09.004","volume":"29","author":"S Sviri","year":"2014","unstructured":"Sviri S, Hashoul J, Stav I, van Heerden PV (2014) Does high-dose vasopressor therapy in medical intensive care patients indicate what we already suspect? J Crit Care 29:157\u2013160. https:\/\/doi.org\/10.1016\/j.jcrc.2013.09.004","journal-title":"J Crit Care"},{"key":"150_CR49","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1097\/SHK.0000000000002109","volume":"59","author":"EJ See","year":"2023","unstructured":"See EJ, Clapham C, Liu J, Khasin M, Liskaser G, Chan JW et al (2023) A pilot study of angiotensin ii as primary vasopressor in critically ill adults with vasodilatory hypotension: the Aramis study. Shock 59:691\u2013696. https:\/\/doi.org\/10.1097\/SHK.0000000000002109","journal-title":"Shock"},{"key":"150_CR50","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1111\/anae.15802","volume":"77","author":"TG Coulson","year":"2022","unstructured":"Coulson TG, Miles LF, Serpa Neto A, Pilcher D, Weinberg L, Landoni G et al (2022) A double-blind randomised feasibility trial of angiotensin-2 in cardiac surgery. Anaesthesia 77:999\u20131009. https:\/\/doi.org\/10.1111\/anae.15802","journal-title":"Anaesthesia"},{"key":"150_CR51","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1053\/j.jvca.2020.08.001","volume":"35","author":"A Klijian","year":"2021","unstructured":"Klijian A, Khanna AK, Reddy VS, Friedman B, Ortoleva J, Evans AS et al (2021) Treatment With Angiotensin II Is Associated With Rapid Blood Pressure Response and Vasopressor Sparing in Patients With Vasoplegia After Cardiac Surgery: A Post-Hoc Analysis of Angiotensin II for the Treatment of High-Output Shock (ATHOS-3) Study. J Cardiothorac Vasc Anesth 35:51\u201358. https:\/\/doi.org\/10.1053\/j.jvca.2020.08.001","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"150_CR52","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1177\/0885066620972943","volume":"37","author":"SE Smith","year":"2022","unstructured":"Smith SE, Newsome AS, Guo Y, Hecht J, McCurdy MT, Mazzeffi MA et al (2022) A multicenter observational cohort study of angiotensin ii in shock. J Intensive Care Med 37:75\u201382. https:\/\/doi.org\/10.1177\/0885066620972943","journal-title":"J Intensive Care Med"},{"key":"150_CR53","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1177\/10600280221099928","volume":"57","author":"S Bird","year":"2023","unstructured":"Bird S, Chand M, Tran TL, Ali S, Awad SS, Cornwell LD et al (2023) Evaluation of the addition of angiotensin II in patients with shock after cardiac surgery at a veterans affairs medical center. Ann Pharmacother 57:141\u2013147. https:\/\/doi.org\/10.1177\/10600280221099928","journal-title":"Ann Pharmacother"},{"key":"150_CR54","doi-asserted-by":"publisher","first-page":"e5","DOI":"10.1016\/j.athoracsur.2018.11.047","volume":"108","author":"A Evans","year":"2019","unstructured":"Evans A, McCurdy MT, Weiner M, Zaku B, Chow JH (2019) Use of angiotensin II for post cardiopulmonary Bypass Vasoplegic Syndrome. Ann Thorac Surg 108:e5-7. https:\/\/doi.org\/10.1016\/j.athoracsur.2018.11.047","journal-title":"Ann Thorac Surg"},{"key":"150_CR55","doi-asserted-by":"publisher","first-page":"359","DOI":"10.4103\/aca.aca_98_21","volume":"25","author":"SB Konkol","year":"2022","unstructured":"Konkol SB, Morrisette MJ, Hulse MC, Enfield KB, Mihalek AD (2022) Outcomes following the use of angiotensin II in patients with postoperative vasoplegic syndrome: a case series. Ann Card Anaesth 25:359\u2013361. https:\/\/doi.org\/10.4103\/aca.aca_98_21","journal-title":"Ann Card Anaesth"},{"key":"150_CR56","doi-asserted-by":"publisher","first-page":"e912","DOI":"10.1097\/CCM.0000000000004502","volume":"48","author":"B Trethowan","year":"2020","unstructured":"Trethowan B, Michaud CJ, Fifer S (2020) Use of angiotensin II in severe vasoplegia after left pneumonectomy requiring cardiopulmonary bypass: a renin response analysis. Crit Care Med 48:e912\u2013e915. https:\/\/doi.org\/10.1097\/CCM.0000000000004502","journal-title":"Crit Care Med"},{"key":"150_CR57","doi-asserted-by":"publisher","first-page":"3080","DOI":"10.1053\/j.jvca.2019.03.004","volume":"33","author":"PM Wieruszewski","year":"2019","unstructured":"Wieruszewski PM, Radosevich MA, Kashani KB, Daly RC, Wittwer ED (2019) Synthetic human angiotensin II for postcardiopulmonary bypass vasoplegic shock. J Cardiothorac Vasc Anesth 33:3080\u20133084. https:\/\/doi.org\/10.1053\/j.jvca.2019.03.004","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"150_CR58","doi-asserted-by":"publisher","first-page":"2756","DOI":"10.1053\/j.jvca.2020.07.087","volume":"35","author":"NS Cutler","year":"2021","unstructured":"Cutler NS, Rasmussen BM, Bredeck JF, Lata AL, Khanna AK (2021) Angiotensin II for critically ill patients with shock after heart transplant. J Cardiothorac Vasc Anesth 35:2756\u20132762. https:\/\/doi.org\/10.1053\/j.jvca.2020.07.087","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"150_CR59","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1053\/j.jvca.2019.03.054","volume":"33","author":"PM Wieruszewski","year":"2019","unstructured":"Wieruszewski PM, Sims CR, Daly RC, Taner T, Wittwer ED (2019) Use of angiotensin II for vasoplegic shock in a combined heart and liver transplant recipient with systolic anterior motion physiology. J Cardiothorac Vasc Anesth 33:2366\u20132367. https:\/\/doi.org\/10.1053\/j.jvca.2019.03.054","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"150_CR60","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1186\/s13054-018-2225-4","volume":"22","author":"M Ostermann","year":"2018","unstructured":"Ostermann M, Boldt DW, Harper MD, Lim GW, Gunnerson K (2018) Angiotensin in ECMO patients with refractory shock. Crit Care 22:288. https:\/\/doi.org\/10.1186\/s13054-018-2225-4","journal-title":"Crit Care"},{"key":"150_CR61","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1213\/ANE.0000000000005953","volume":"134","author":"M Meersch","year":"2022","unstructured":"Meersch M, Weiss R, Massoth C, K\u00fcllmar M, Saadat-Gilani K, Busen M et al (2022) The association between angiotensin ii and renin kinetics in patients after cardiac surgery. Anesth Analg 134:1002\u20131009. https:\/\/doi.org\/10.1213\/ANE.0000000000005953","journal-title":"Anesth Analg"},{"key":"150_CR62","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1053\/j.jvca.2022.11.019","volume":"37","author":"ML Montgomery","year":"2023","unstructured":"Montgomery ML, Gross CR, Lin H-M, Ouyang Y, Levin MA, Corkill HE et al (2023) Plasma Renin Activity Increases With Cardiopulmonary Bypass and is Associated With Vasoplegia After Cardiac Surgery. J Cardiothorac Vasc Anesth 37:367\u2013373. https:\/\/doi.org\/10.1053\/j.jvca.2022.11.019","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"150_CR63","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.bja.2023.06.056","volume":"131","author":"TG Coulson","year":"2023","unstructured":"Coulson TG, Miles LF, Zarbock A, Burrell LM, Patel SK, von Groote T et al (2023) Renin-angiotensin-aldosterone system dynamics after targeted blood pressure control using angiotensin II or norepinephrine in cardiac surgery: mechanistic randomised controlled trial. Br J Anaesth 131:664\u2013672. https:\/\/doi.org\/10.1016\/j.bja.2023.06.056","journal-title":"Br J Anaesth"},{"key":"150_CR64","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1164\/rccm.202005-2050OC","volume":"203","author":"M K\u00fcllmar","year":"2021","unstructured":"K\u00fcllmar M, Saadat-Gilani K, Weiss R, Massoth C, Lagan A, Cort\u00e9s MN et al (2021) Kinetic changes of plasma renin concentrations predict acute kidney injury in cardiac surgery patients. Am J Respir Crit Care Med 203:1119\u20131126. https:\/\/doi.org\/10.1164\/rccm.202005-2050OC","journal-title":"Am J Respir Crit Care Med"},{"key":"150_CR65","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/j.jtcvs.2021.02.097","volume":"163","author":"JH Chow","year":"2022","unstructured":"Chow JH, Wittwer ED, Wieruszewski PM, Khanna AK (2022) Evaluating the evidence for angiotensin II for the treatment of vasoplegia in critically ill cardiothoracic surgery patients. J Thorac Cardiovasc Surg 163:1407\u20131414. https:\/\/doi.org\/10.1016\/j.jtcvs.2021.02.097","journal-title":"J Thorac Cardiovasc Surg"},{"key":"150_CR66","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13054-020-2743-8","volume":"24","author":"LW Busse","year":"2020","unstructured":"Busse LW, Barker N, Petersen C (2020) Vasoplegic syndrome following cardiothoracic surgery-review of pathophysiology and update of treatment options. Crit Care 24:36. https:\/\/doi.org\/10.1186\/s13054-020-2743-8","journal-title":"Crit Care"},{"key":"150_CR67","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1161\/HYPERTENSIONAHA.110.158220","volume":"56","author":"EY Senchenkova","year":"2010","unstructured":"Senchenkova EY, Russell J, Almeida-Paula LD, Harding JW, Granger DN (2010) Angiotensin II-mediated microvascular thrombosis. Hypertension 56:1089\u20131095. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.110.158220","journal-title":"Hypertension"},{"key":"150_CR68","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1160\/TH04-10-0701","volume":"93","author":"A Mogielnicki","year":"2005","unstructured":"Mogielnicki A, Chabielska E, Pawlak R, Szemraj J, Buczko W (2005) Angiotensin II enhances thrombosis development in renovascular hypertensive rats. Thromb Haemost 93:1069\u20131076. https:\/\/doi.org\/10.1160\/TH04-10-0701","journal-title":"Thromb Haemost"},{"key":"150_CR69","doi-asserted-by":"publisher","first-page":"559","DOI":"10.2450\/2015.0277-14","volume":"13","author":"A Malato","year":"2015","unstructured":"Malato A, Dentali F, Siragusa S, Fabbiano F, Kagoma Y, Boddi M et al (2015) The impact of deep vein thrombosis in critically ill patients: a meta-analysis of major clinical outcomes. Blood Transfus 13:559\u2013568. https:\/\/doi.org\/10.2450\/2015.0277-14","journal-title":"Blood Transfus"},{"key":"150_CR70","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.chest.2020.08.2074","volume":"159","author":"PM Wieruszewski","year":"2021","unstructured":"Wieruszewski PM, Wittwer ED, Kashani KB, Brown DR, Butler SO, Clark AM et al (2021) Angiotensin II infusion for shock: a multicenter study of postmarketing use. Chest 159:596\u2013605. https:\/\/doi.org\/10.1016\/j.chest.2020.08.2074","journal-title":"Chest"},{"key":"150_CR71","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/01.ccm.0000528062.45598.be","volume":"46","author":"H Szerlip","year":"2018","unstructured":"Szerlip H, Bihorac A, Chang S, Chung K, H\u00e4stbacka J, Murugan R et al (2018) 6: effect of disease severity on survival in patients receiving angiotensin ii for vasodilatory shock. Crit Care Med 46:3. https:\/\/doi.org\/10.1097\/01.ccm.0000528062.45598.be","journal-title":"Crit Care Med"},{"key":"150_CR72","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s13054-023-04446-1","volume":"27","author":"PM Wieruszewski","year":"2023","unstructured":"Wieruszewski PM, Bellomo R, Busse LW, Ham KR, Zarbock A, Khanna AK et al (2023) Initiating angiotensin II at lower vasopressor doses in vasodilatory shock: an exploratory post-hoc analysis of the ATHOS-3 clinical trial. Crit Care 27:175. https:\/\/doi.org\/10.1186\/s13054-023-04446-1","journal-title":"Crit Care"},{"key":"150_CR73","doi-asserted-by":"publisher","first-page":"e0623","DOI":"10.1097\/CCE.0000000000000623","volume":"4","author":"M Quan","year":"2022","unstructured":"Quan M, Cho N, Bushell T, Mak J, Nguyen N, Litwak J et al (2022) Effectiveness of angiotensin ii for catecholamine refractory septic or distributive shock on mortality: a propensity score weighted analysis of real-world experience in the medical ICU. Crit Care Explor 4:e0623. https:\/\/doi.org\/10.1097\/CCE.0000000000000623","journal-title":"Crit Care Explor"},{"key":"150_CR74","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1097\/CCM.0000000000003092","volume":"46","author":"JA Tumlin","year":"2018","unstructured":"Tumlin JA, Murugan R, Deane AM, Ostermann M, Busse LW, Ham KR et al (2018) Outcomes in Patients with Vasodilatory Shock and Renal Replacement Therapy Treated with Intravenous Angiotensin II. Crit Care Med 46:949\u2013957. https:\/\/doi.org\/10.1097\/CCM.0000000000003092","journal-title":"Crit Care Med"},{"key":"150_CR75","unstructured":"38th International Symposium on Intensive Care and Emergency Medicine - PMC n.d. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5883106\/ (Accessed 24 Nov 2023)"},{"key":"150_CR76","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1186\/s13054-020-02928-0","volume":"24","author":"A Zangrillo","year":"2020","unstructured":"Zangrillo A, Landoni G, Beretta L, Morselli F, Serpa Neto A, Bellomo R et al (2020) Angiotensin II infusion in COVID-19-associated vasodilatory shock: a case series. Crit Care 24:227. https:\/\/doi.org\/10.1186\/s13054-020-02928-0","journal-title":"Crit Care"},{"key":"150_CR77","doi-asserted-by":"publisher","first-page":"e0230","DOI":"10.1097\/CCE.0000000000000230","volume":"2","author":"DE Leisman","year":"2020","unstructured":"Leisman DE, Mastroianni F, Fisler G, Shah S, Hasan Z, Narasimhan M et al (2020) Physiologic response to angiotensin II treatment for coronavirus disease 2019-induced vasodilatory shock: a retrospective matched cohort study. Crit Care Explor 2:e0230. https:\/\/doi.org\/10.1097\/CCE.0000000000000230","journal-title":"Crit Care Explor"},{"key":"150_CR78","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.1002\/jmv.27592","volume":"94","author":"A Serpa Neto","year":"2022","unstructured":"Serpa Neto A, Landoni G, Ostermann M, Lumlertgul N, Forni L, Alvarez-Belon L et al (2022) Angiotensin II infusion in COVID-19: an international, multicenter, registry-based study. J Med Virol 94:2079\u20132088. https:\/\/doi.org\/10.1002\/jmv.27592","journal-title":"J Med Virol"},{"key":"150_CR79","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1164\/rccm.201911-2172OC","volume":"202","author":"R Bellomo","year":"2020","unstructured":"Bellomo R, Forni LG, Busse LW, McCurdy MT, Ham KR, Boldt DW et al (2020) Renin and survival in patients given angiotensin II for catecholamine-resistant vasodilatory shock. A clinical trial. Am J Respir Crit Care Med 202:1253\u201361. https:\/\/doi.org\/10.1164\/rccm.201911-2172OC","journal-title":"Am J Respir Crit Care Med"},{"key":"150_CR80","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1097\/CCM.0000000000002441","volume":"45","author":"LW Busse","year":"2017","unstructured":"Busse LW, Wang XS, Chalikonda DM, Finkel KW, Khanna AK, Szerlip HM et al (2017) Clinical experience with IV angiotensin II administration: a systematic review of safety. Crit Care Med 45:1285\u20131294. https:\/\/doi.org\/10.1097\/CCM.0000000000002441","journal-title":"Crit Care Med"}],"container-title":["Journal of Anesthesia, Analgesia and Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s44158-024-00150-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s44158-024-00150-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s44158-024-00150-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T06:55:48Z","timestamp":1740034548000},"score":1,"resource":{"primary":{"URL":"https:\/\/janesthanalgcritcare.biomedcentral.com\/articles\/10.1186\/s44158-024-00150-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,21]]},"references-count":80,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["150"],"URL":"https:\/\/doi.org\/10.1186\/s44158-024-00150-w","relation":{},"ISSN":["2731-3786"],"issn-type":[{"value":"2731-3786","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,21]]},"assertion":[{"value":"8 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13"}}